Ketoconazole and Mirabegron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ketoconazole and Mirabegron. Common interactions include myalgia among females and colon cancer among males.

The phase IV clinical study analyzes what interactions people who take Ketoconazole and Mirabegron have. It is created by eHealthMe based on reports of 14 people who take Ketoconazole and Mirabegron from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On May, 22, 2022

14 people who take Ketoconazole and Mirabegron together, and have interactions are studied.


What is Ketoconazole?

Ketoconazole has active ingredients of ketoconazole. It is often used in fungal infection. eHealthMe is studying from 11,177 Ketoconazole users for its effectiveness, alternative drugs and more.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. eHealthMe is studying from 2,572 Mirabegron users for its effectiveness, alternative drugs and more.

Number of Ketoconazole and Mirabegron reports submitted per year:

Ketoconazole and Mirabegron drug interactions.

Common Ketoconazole and Mirabegron drug interactions by gender *:

female:

  1. Myalgia
  2. Asthenia
  3. Pyrexia

male:

  1. Colon cancer
  2. Pulmonary embolism
  3. Hiccups
  4. Meningitis
  5. Nausea
  6. Neurotoxicity
  7. Plasma cell myeloma
  8. Prostatic disorder
  9. Respiratory failure
  10. Tachycardia

Common Ketoconazole and Mirabegron drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Dyspnoea
  2. Hiccups
  3. Nausea
  4. Respiratory failure
  5. Tachycardia
  6. Vomiting

60+:

  1. Colon cancer
  2. Myalgia
  3. Neurotoxicity
  4. Plasma cell myeloma
  5. Pyrexia
  6. Pulmonary embolism
  7. Second primary malignancy
  8. Deep vein thrombosis
  9. Urinary retention
  10. Arthralgia

Common conditions people have *:

  1. Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 6 people, 42.86%
  2. High Blood Pressure: 5 people, 35.71%
  3. Diabetes: 3 people, 21.43%
  4. Constipation: 3 people, 21.43%
  5. Multiple Myeloma (cancer of the plasma cells): 3 people, 21.43%
  6. Pain: 3 people, 21.43%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 21.43%
  8. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 21.43%
  9. Prostatomegaly (enlargement of the prostate): 2 people, 14.29%
  10. Iron Deficiency: 2 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Ketoconazole and Mirabegron?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Ketoconazole and Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ketoconazole interactions:

Browse all interactions between Ketoconazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Mirabegron interactions:

Browse all interactions between Mirabegron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ketoconazole and mirabegron (the active ingredients of Ketoconazole and Mirabegron, respectively), and Ketoconazole and Mirabegron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: